Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma
Additional locations may be listed on ClinicalTrials.gov for NCT05907954.
Locations matching your search criteria
United States
California
La Jolla
UC San Diego Moores Cancer CenterStatus: Active
Name Not Available
Los Angeles
UCLA / Jonsson Comprehensive Cancer CenterStatus: Active
Contact: Maria Zamudio
Phone: 310-794-2971
Palo Alto
Stanford Cancer Institute Palo AltoStatus: Temporarily closed to accrual
Name Not Available
Minnesota
Rochester
Mayo Clinic in RochesterStatus: Active
Name Not Available
North Carolina
Durham
Duke University Medical CenterStatus: Active
Name Not Available
Pennsylvania
Philadelphia
Thomas Jefferson University HospitalStatus: Temporarily closed to accrual
Name Not Available
Texas
Dallas
UT Southwestern/Simmons Cancer Center-DallasStatus: Active
Name Not Available
Phase 2 multi-center open-label IDE196 study in patients with primary uveal melanoma (UM)
requiring either enucleation or plaque brachytherapy. Patients will be treated in
neoadjuvant setting up to 12 months (or maximum benefit) followed by primary local
therapy. An additional 6 months of adjuvant treatment may be given to some patients. All
patients will have long term follow-up (up to 3 years) to assess visual outcome, disease
recurrence, and development of metastatic disease.
Lead OrganizationIDEAYA Biosciences
Principal InvestigatorMatthew John Maurer
